CClinicalTrials.gg
Not yet recruitingNCT07628257GlioConnectUpdated Jun 4, 2026

Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up

An interventional study of 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences in Glioblastoma, sponsored by Centre Paul Strauss. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Centre Paul Strauss · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms.

This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.

02

Conditions studied

  • Glioblastoma

Browse trials for

03

In context

Glioblastoma

1,920 studies on the registry are indexed under Glioblastoma; 450 are open to participants now.

This study's planned enrollment of 80 is above the median of 36 across 1,618 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Centre Paul Strauss is the lead sponsor of 30 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients
  • Patients with glioblastoma
  • Patients treated in the Nuclear Medicine \& Molecular Imaging Department of the Strauss Institute for PET/MRI scans for:

    • Preoperative metabolic evaluation of a brain-expanding lesion

Exclusion criteria

Exclusion Criteria:

  • Contraindications to MRI
  • Minor or incapacitated adult
  • Patient deprived of liberty
  • Patient under legal guardianship
  • Patient unable to consent
  • Pregnant or breastfeeding woman
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Patients with glioblastoma treated in the Department of Nuclear Medicine & Molecular Imaging

    Other: 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences

Interventions

  • Other18F-FDG PET/MRI with additional DTI and rs-fMRI sequences

    fluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests

06

What researchers measure

Primary outcomes

  1. Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery

    Time frame: Before surgery

Secondary outcomes

  1. correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance after surgery

    Time frame: After surgery, through the study, i.e. for a maximum of 2 years

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07628257
Lead sponsor
Centre Paul Strauss
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Sep 15, 2030 (estimated)
Completion
Sep 15, 2030 (estimated)
Last update
Jun 4, 2026

Study contacts

Claire VIT
Contact
promotion-rc@institut-strauss.fr
(0)388258529 ext. +33
Manon VOEGELIN
Contact
promotion-rc@institut-strauss.fr
(0)368339523 ext. +33
Izzie-Jacques NAMER, MD, PhD
principal investigator · Institut Public De Cancerologie Strauss Europe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion